# Advantagene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advantagene

- Industry: Pharmaceuticals
- Headquarters: Needham, US
- Website: www.candeltx.com
- Total disclosed funding: $51M
- Latest round: Series C (Apr 1, 2019)
- Investors on record: 5

## About

Based in Massachusetts, US, and was founded in 1999 by Estuardo Aguilar-Cordova. Advantagene, Inc., which now trades as Candel Therapeutics, develops cancer immunotherapies to help cancer patients and their families live better lives. Immunotherapies developed by the firm are aimed at preventing cancer recurrence and progression while posing little harm. In clinical studies, the firm is studying the benefits of CAN-2409 therapy for prostate cancer as of July 2021. Candel Therapeutics trades on the NASDAQ under the name CADL. In July 2021, the business held an initial public offering (IPO) and raised $234 million.

Advantagene, Inc. is a clinical-stage biotechnology firm that develops Gene Mediated Cytotoxic Immunotherapy (GMCI), which causes immunogenic cell death in cancer cells at the injection site and prevents cancer recurrence and progression with minimal side effects. Clinically Advanced Solid Tumor Immunotherapy (CAN-2409) is another product offered by the business, which eliminates the need for complicated immune evasion or tumor-specific targeting mechanisms by focusing the immune response locally towards the tumor.

The Phase 3 study for CAN-2409 will be completed in Q3 of 2021, with a final data readout in 2024, according to the firm.

## Funding rounds

- Series C, Apr 1, 2019, $23M — Sands Capital Alternatives, Northpond Ventures, Level One Fund, H7 Holdings
- Series B, Jan 4, 2019, $29M — PBM Capital Group

## Investors

- PBM Capital Group (https://capitalatlas.ai/funds/pbm-capital-group) — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series C
- Level One Fund (https://capitalatlas.ai/funds/level-one-fund) — Series C
- H7 Holdings — Series C